Feature | June 05, 2014

FFR Remains Gold Standard in Determining Severity of Coronary Artery Blockages

VERIFY-2 study finds two new coronary lesion assessment measures do not provide sufficient accuracy

June 5, 2014 — New measures of the severity of coronary artery blockages do not provide enough accuracy to guide treatment decisions, according to the results of the VERIFY-2 study presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.

To aid decisions before performing percutaneous coronary intervention (PCI), interventional cardiologists can use several types of assessments that measure whether a blockage in the coronary artery is limiting blood flow to the heart. Fractional flow reserve (FFR) is a validated technique that measures pressure differences across the blockage. FFR-guided PCI improves outcomes compared to angiography alone. However, some interventional cardiologists have been hesitant to use FFR because it requires administration of the drug adenosine, which may not be well tolerated in some patients and adds time to the procedure.

Instantaneous wave-free ratio (iFR) is a new measure that assesses the pressure difference across a stenosis during a specific period of the cardiac cycle. It is measured at rest and does not require the administration of adenosine. Another index of stenosis severity, Pd/Pa, is also measured at rest and without adenosine, but unlike iFR, it does not require any specific measurement software. The previous VERIFY and RESOLVE studies indicated that both iFR and Pd/Pa have similar levels of diagnostic accuracy (about 80 percent) when compared to FFR. The recent ADVISE II study demonstrated that a hybrid strategy using a combination of iFR and FFR correctly classified 94 percent of lesions compared to a strategy of using FFR in all patients, while avoiding the use of adenosine in two-thirds of the patients in the study.

“The measurement of iFR has recently been introduced to aid interventional cardiologists in their assessment of coronary lesions without the need for adenosine,” said Stuart Watkins, M.D., consultant cardiologist at the Golden Jubilee National Hospital in Glasgow, Scotland.“VERIFY-2 was designed to evaluate the accuracy of this measurement compared to Pd/Pa using FFR as the currently accepted gold standard.”

In the study presented at SCAI, researchers examined two hybrid assessment strategies: iFR-FFR with an adenosine-zone of 0.86-0.93, and Pd/Pa-FFR with an adenosine-zone of 0.87-0.94. A total of 97 patients with 120 coronary artery blockages were assessed.

They found 10.1 percent of lesions were misclassified using iFR-FFR, compared to 6.3 percent using Pd/Pa-FFR.

Next, they compared the accuracy of iFR and Pd/Pa compared to FFR using binary cut-off values of 0.90 for iFR and 0.92 for Pd/Pa. In this analysis, the use of iFR alone would result in inappropriate PCI in 8.3 percent of lesions and incomplete revascularization in another 10 percent. Using Pd/Pa alone would result in inappropriate PCI in 4.2 percent of lesions and incomplete revascularization in another 10.8 percent.

Researchers concluded that both hybrid decision-making strategies and the use of binary cut-off values resulted in similar levels of lesion misclassification compared to FFR.

“FFR remains the gold standard – we have concluded neither iFR nor Pd/Pa is sufficiently accurate to guide decisions on the need for revascularization,” said Watkins. “Although these measures aren’t accurate enough to replace FFR, this study adds to our body of knowledge as we work to identify the most effective ways to measure lesion severity.”

Watkins reported no disclosures. The title of the presentation was “Comparison of Lesion Level Decision Making in the Cath Lab Using Hyperemic and Non-hyperemic Pressure Wire Derived Indices of Stenosis Severity: The VERIFY-2 Study.”

For more information: www.scai.org

Related Content

bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system


Feature | Stents Bioresorbable| October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular S
Avinger, Pantheris atherectomy catheter, OCT, Lumivascular technology, expanded FDA indication, diagnostic imaging device
News | Atherectomy Devices| October 20, 2016
Avinger Inc. recently announced that the company has received expanded indications from the U.S. Food and Drug...
St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
recall, alligator retrieval device, X-Celerator hydrophilic guidewire, UltraFlow flow directed micro catheters, Marathon flow directed micro catheters
News | Cath Lab| October 18, 2016
Medtronic plc announced last week that it has notified customers of a voluntary recall of certain lots of its Pipeline...
Inventory management, Cardinal, RFID inventory tracking, cath lab inventory
Sponsored Content | Whitepapers | Inventory Management| October 18, 2016
As healthcare moves into the era of bundled payments, providers need to be especially focused on ensuring delivery of
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid| October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
3-D bioprinting, 3-D printing, printed organs, 3D bioprinting

3-D printed vessel made from living cells implanted in an animal to test feasibility of using such structures clinically. Blood vessels are a stepping stone to the creation of more complex 3-D printed organs made from biomaterials. Image from the South Carolina Project for Organ Biofabrication.


Feature | 3-D Printing| October 13, 2016 | Dave Fornell
The U.S. Food and Drug Administration (FDA) changed its rules concerning custom medical devices Oct.
Overlay Init